Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...

This infographic, the first in a three-part series, explores the development of resistance to endocrine therapy in ...

Novartis wins EC approval for Kisqali in a broad population of patients with HR+/HER2- early breast cancer at high risk of ...

Basel: Novartis has announced that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an ...

Novartis Kisqali receives European approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence: Basel Thursday, November 28, 2024, 09: ...

An expert discusses the next steps for patients with metastatic breast cancer after their disease no longer responds to ...

Novartis announced today that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone ...

The European Commission (EC) has granted approval to Novartis' Kisqali (ribociclib), plus an aromatase inhibitor to treat ...

Novartis (NVS) announced that the European Commission, EC, has approved Kisqali in combination with an aromatase inhibitor, AI, for the ...

Novartis has secured European Commission approval for Kisqali® (ribociclib) in combination with endocrine therapy (ET) as an ...

Following recent data announcements at ESMO 20246, Novartis will continue to evaluate NATALEE patients for longer-term ...

Mayo Clinic Comprehensive Cancer Center experts highlight breast cancer research that may reduce or eliminate the need for chemotherapy and endocrine treatments and may allow for shorter and less ...